Lubna N Chaudhary
Overview
Explore the profile of Lubna N Chaudhary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamaraju S, Fowler A, Tarima S, Chaudhary L, Burkard M, Giever T, et al.
Clin Breast Cancer
. 2025 Jan;
PMID: 39824712
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients...
2.
Alaklabi S, Roy A, Zagami P, Chakraborty A, Held N, Elijah J, et al.
JCO Oncol Pract
. 2024 Oct;
:OP2400242.
PMID: 39353151
Purpose: Sacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC....
3.
Valencia E, Cortina C, Cobb A, Chaudhary L, Kelly T, Kong A
Ann Surg Open
. 2024 Sep;
5(3):e465.
PMID: 39310356
Objective: To assess the accuracy, quality, and readability of patient-focused breast cancer websites using expert evaluation and validated tools. Background: Ensuring access to accurate, high-quality, and readable online health information...
4.
Krishnan J, Patel A, Roy A, Alharbi M, Kapoor A, Yao S, et al.
Clin Breast Cancer
. 2024 Aug;
24(8):e701-e711.e2.
PMID: 39198116
Background: Pembrolizumab combined with neoadjuvant chemotherapy (NAC) is the current standard of care in early stage triple-negative breast cancer (TNBC) based on higher event-free survival and pathological complete response (pCR)...
5.
Jorns J, Sun Y, Kamaraju S, Cheng Y, Kong A, Yen T, et al.
J Pers Med
. 2024 May;
14(5).
PMID: 38793060
PD-L1 immunohistochemistry (IHC) has become an established method for predicting cancer response to targeted anti-PD1 immunotherapies, including breast cancer (BC). The alternative PD-1 ligand, PD-L2, remains understudied but may be...
6.
Alaklabi S, Roy A, Chaudhary L, Gandhi S
Explor Target Antitumor Ther
. 2024 Jan;
4(6):1301-1309.
PMID: 38213539
Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for...
7.
Pierro M, Zurko J, Szabo A, Cheng Y, Kamaraju S, Burfeind J, et al.
WMJ
. 2024 Jan;
122(5):418-421.
PMID: 38180937
Introduction: In this retrospective matched case control study, we aim to identify breast cancer-related risk factors associated with developing COVID-19 and describe outcomes of patients with breast cancer diagnosed with...
8.
Gonzalez T, Nie Q, Chaudhary L, Basel D, Reddi H
Cancer Genet
. 2023 Dec;
282-283:1-8.
PMID: 38134587
Background: Early detection of breast cancer would help alleviate the burden of treatment for early-stage breast cancer and help patient prognosis. There is currently no established gene panel that utilizes...
9.
Rogers C, Cobb A, Lloren J, Chaudhary L, Johnson M, Huang C, et al.
Breast Cancer Res Treat
. 2023 Oct;
203(2):317-328.
PMID: 37864105
Purpose: Neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) allows for assessment of tumor pathological response and has survival implications. In 2017, the CREATE-X trial demonstrated survival benefit with adjuvant...
10.
Chaudhary L, Jorns J, Sun Y, Cheng Y, Kamaraju S, Burfeind J, et al.
Breast Cancer Res Treat
. 2023 Jul;
201(3):387-396.
PMID: 37460683
Background: Endocrine resistant metastatic disease develops in ~ 20-25% of hormone-receptor-positive (HR+) breast cancer (BC) patients despite endocrine therapy (ET) use. Upregulation of HER family receptor tyrosine kinases (RTKs) represent...